Document

APACHE III score predicts mortality in out of hospital cardiac arrest (OOHCA) patients with non-ST elevation myocardial infarction (NSTEMI)

There are few data to help guide in the decision of when and whether a patient presenting with OOHCA and NSTEMI should under angiogram and PCI. Which guides is difficult to determine.

C. Tie, T. Kuang, J. Loubser, C. Frampton, D. Knight, D. Smyth
Canterbury District Health Board, Christchurch
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

APACHE III score predicts mortality in out of hospital cardiac arrest (OOHCA) patients with ST elevation myocardial infarction (STEMI)

Coronary angiogram and percutaneous coronary intervention (PCI) is established treatment for STEMI. However, in patients who have OOHCA and STEMI, its efficacy is less certain.

C. Tie, T. Kuang, J. Loubser, C. Frampton, D. Knight, D. Smyth
Canterbury District Health Board, Christchurch
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Bleeding risk and incidence in real world percutaneous coronary intervention patients with ticagrelor

To investigate the incidence and severity of bleeding at discharge and 30 days in real world clinical practice with Ticagrelor in patients undergoing PCI.

I. Subiakto, A. Ul Haq, W. Van Gaal
The Northern Hospital, Epping, Sydney, Australia
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

How well are we doing in secondary prevention after myocardial infarction – The STABILITY study experience

Compliance with preventive medications after myocardial infarction is known to be suboptimal in New Zealand (NZ), and to worsen over time. Patients who participate in clinical trials may have better compliance and risk factor control. This study describes achievement of standard of care goals in NZ participants compared to those from the rest of the world in the global STABILITY study. This study evaluated the effects of darapladib on top of best care on cardiovascular death, MI and stroke in high risk patients with established cardiovascular disease.

R. Stewart, J. Benetar, A. Hamer, D. Scott, G. Devom, H. Hart, J. Elliott, J. Tisch, L. Davidson, M. Hills, N. Harrison, R. Rankin, T. O’Meeghan, V. Chen, H. White

Balloon aortic valvuloplasty (BAV) for the management of severe aortic stenosis in the era of transcatheter aortic valve implantation (TAVI)

The advent of TAVI has seen resurgence in BAV for both bridging and palliation of patients with symptomatic severe aortic stenosis (AS).

K. Sree Raman, R. Nair, G. Devlin, S. Pasupati
Waikato Hospital, Hamilton
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Percutaneous coronary intervention rates and outcomes of coronary angiography in patients with prior CABG – an ANZACS-QI single centre study

Coronary angiography in patients with previous coronary artery bypass grafts(CABG) is technically more difficult, increases lab time, radiation exposure and has been linked to higher in-hospital complications and mortality. We sought to study this by comparing those who underwent coronary angiography with previous CABG versus those without.

G. Sathananthan, C. Flynn, D. Scott, P. Kay, W. Harrison, A. Kerr
Middlemore Hospital, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Novel approach to improving cardiac rehabilitation for all: The whanau ora way

Home based cardiac rehabilitation (CR) is an evidenced based intervention that provides further choice of CR interventions for patients after a cardiac event. Te Hononga O Tamaki Me Hoturoa is a kaupapa Maori non-government organisation that has been delivering home based CR for the past six years.

L. Sami, S. Christophers, A. Kerr, A. Mclachan
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Circulating cardiovascular microRNAs as diagnostic biomarkers for early diagnosis of diabetic heart disease

Heart disease in diabetics develops at a much early stage, but is often unrecognized due to the absence of pathognomonic signs, thereby restricting its early detection and active therapeutic management. Identifying the early modulators in diabetic heart disease (DHD) will not only help in early detection of the disease, but also allow sufficient time for optimisation of the treatment. Recently microRNAs (miRs) are gaining interest as diagnostic biomarkers for several diseases including cardiovascular diseases due to their stability in circulation and tissue specificity.

S. Rawal, J. Paulin, E. Munasinghe, P. Manning, R. Katare
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?